Cardiovascular Toxicities of Androgen Deprivation Therapy

Androgen deprivation therapy (ADT), a key treatment for prostate cancer, was linked to adverse cardiovascular events, with emerging data suggesting that GnRH antagonists might pose a lower cardiovascular risk compared to agonists. Ongoing clinical trials were evaluating the safety of various ADT modalities, and racial disparities in cardiovascular outcomes among prostate cancer patients were being investigated. Additionally, there was an intriguing potential connection between ADT and a reduced risk of COVID-19 infection and severity. Recognizing the cardiotoxicity of ADT and implementing aggressive risk factor modification were deemed crucial for optimal patient care.